secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHIMERIX INC (—)
CIK:        0001117480
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001193125-25-087237
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharmaceuticals completes $8.55/share acquisition of Chimerix; 90.45% of shares tendered
--------------------------------------------------------------------------------

- Offer expired April 17, 2025; 84,845,016 shares validly tendered (~90.45% outstanding).
- Purchaser merged into Chimerix on April 21, 2025; Chimerix becomes indirect wholly owned subsidiary of Jazz.
- All pre-merger directors resigned; Alan Campion named sole director and CFO; Andrea Burke VP.
- Company notified Nasdaq of delisting; intends to file Form 15 to terminate SEC reporting obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1117480/000119312525087237/0001193125-25-087237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1117480/000119312525087237/d942664d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-087237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer